Dr. Herzog is interested in how the tumor microenvironment (TME) impacts the progression and response to therapy in lung cancer. Recent advances in immune-based therapy have improved outcomes for many lung cancer patients. Yet, despite the observed benefit of immune checkpoint blockade in the locally advanced and metastatic setting, not all patients respond to these […]
Dr. Brett Herzog joins the Department of Medicine















































